<DOC>
	<DOCNO>NCT00001066</DOCNO>
	<brief_summary>To compare efficacy lamivudine ( 3TC ) zidovudine ( AZT ) combination versus good didanosine ( ddI ) monotherapy ddI/AZT combination , symptomatic HIV-1 infected child receive less 56 day prior antiretroviral therapy . To evaluate safety tolerance 3TC/AZT patient population . To determine measure diseases response study regimen . Currently , none potential treatment HIV-1 infection proven nontoxic effective long-term use . However , previous study adult child show 3TC combined AZT reduce HIV load blood increase white blood cell . Additionally , 3TC demonstrate favorable safety profile .</brief_summary>
	<brief_title>A Comparison Zidovudine Plus Lamivudine Versus ddI Used Alone Combination With Zidovudine HIV-1 Infected Children</brief_title>
	<detailed_description>Currently , none potential treatment HIV-1 infection proven nontoxic effective long-term use . However , previous study adult child show 3TC combined AZT reduce HIV load blood increase white blood cell . Additionally , 3TC demonstrate favorable safety profile . Patients randomize receive oral 3TC/AZT , ddI/AZT , ddI alone least 24 month . PER AMENDMENT 4/29/96 : NOTE : Randomization ZDV+ddI arm terminate Spring 1996 base upon result ACTG 152 . Patients arm continue blind study drug follow end study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : IVIG . Prophylaxis opportunistic infection . EPO . GCSF GMCSF . Patients must : Symptomatic HIV infection . Less 56 day prior antiretroviral therapy . Consent parent guardian . NOTE : Coenrollment ACTG 219 , ACTG 220 , certain ACTG opportunistic infection protocol permit . Prior Medication : Allowed : Up 56 day prior antiretroviral therapy . Prior immunomodulator therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malignancy . Hypersensitivity nucleoside analog . Current grade 2 high amylase/lipase toxicity grade 3 4 toxicity . PER AMENDMENT 4/29/96 : Active opportunistic infection and/or serious bacterial infection time entry . Concurrent Medication : Excluded : Any antiHIV therapy . Megestrol acetate ( Megace ) . Probenecid . IV pentamidine . Human growth hormone ( hGH ) . Systemic corticosteroid 2 week . Prior Medication : Excluded : Investigational drug therapy within 14 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Lamivudine</keyword>
</DOC>